US3926188A - Laminated drug dispenser - Google Patents

Laminated drug dispenser Download PDF

Info

Publication number
US3926188A
US3926188A US523720A US52372074A US3926188A US 3926188 A US3926188 A US 3926188A US 523720 A US523720 A US 523720A US 52372074 A US52372074 A US 52372074A US 3926188 A US3926188 A US 3926188A
Authority
US
United States
Prior art keywords
drug
dispenser
lamina
agent
laminate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US523720A
Other languages
English (en)
Inventor
Richard W Baker
Robert M Gale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Priority to US523720A priority Critical patent/US3926188A/en
Priority to GB4228975A priority patent/GB1477813A/en
Priority to DE2549856A priority patent/DE2549856C2/de
Priority to IT69740/75A priority patent/IT1050619B/it
Priority to JP50136148A priority patent/JPS6059203B2/ja
Priority to CA239,459A priority patent/CA1056685A/en
Priority to CH1472575A priority patent/CH634226A5/de
Priority to SE7512744A priority patent/SE439432B/xx
Priority to MX161923A priority patent/MX158868A/es
Priority to MX6132A priority patent/MX158867A/es
Priority to FR7534821A priority patent/FR2290891A1/fr
Application granted granted Critical
Publication of US3926188A publication Critical patent/US3926188A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time

Definitions

  • Mandell 5 7 ABSTRACT A three layer laminate drug dispenser comprising a core lamina of a crystalline drug of low water solubility dispersed homogeneously in a polymer matrix of permeability, P, to the drug, the lamina having a thickness, 2!, and a surface area, A, interposed between outer laminas made of a drug release rate controlling polymer of permeability, P, to the drug, each outer lamina having a thickness, z',and the combined, exposed surface area of the outer laminas being A wherein the expression and the expression A P r 2; (DA 3 I 13 Claims, 5 Drawing Figures U.S. Patent De c. 16, 1975 Sheet 1 of2 3,926,188
  • This invention relates to a laminated dispenser for dispensing active agents by a diffusion mechanism. More specifically it relates to dispensers comprising a three layer sandwich-type laminate which dispense crystalline drugs of low water solubility.
  • sustained release dispensers particularly ones for dispensing drugs, have been developed recently which comprise an active agent which is confined within a polymer and which dispense an agent by a diffusion mechanism in which the agent permeates through the polymer.
  • the aim of these devices is to dispense the drug at a more or less constant rate for a prolonged period of time which results in improved therapy compared to drugs delivered by periodic ingestion of pills, injections or drops.
  • Such dispensers are of two types: monolithic and reservoir.
  • a monolithic device the drug or other active agent is dispersed in a polymer which is permeable to the drug.
  • the time rate of release of agent from such devices has been studied and reported. It is proportional to time
  • a plot of release rate versus time for a monolithic device gives a curve which starts at a high rate and continuously declines. Notwithstanding this varying release rate, monolithic devices have the commercial attractiveness of being inexpensive to make.
  • embodiments of reservoir devices in which the agent release is substantially constant are disclosed.
  • the two basic features of those embodiments which permit such release are: formulating the agent in a liquid or solid carrier whose permeability to the drug is greater than the permeability of the polymer defining the container to the agent; and maintaining the concentration of the agent in the carrier at saturation for the effective dispensing lifetime of the device.
  • Such reservoir embodiments are the only type of diffusion device for dispensing the agent at a practical controlled rate.
  • Such embodiments also provide the advantages of providing a substantially constant release of agent-- which is an important factor as regards efficacy and safety in many therapeutic regimens.
  • the disadvantages of reservoir devices as compared to monolithic devices is economic--the former being more complex and hence more costly to make than the latter.
  • the laminated drug dispenser of this invention may be in the form of a three layered sandwich or in the form of a concentric laminate. This type of device combines the good drug release kinetics of the reservoir devices with the ease and cheapness of manufacture of monolithic devices.
  • FIG. 1 is a cross-sectional view of a drug dispenser of this invention
  • FIG. 2 is a graphical representation of the release rates of the devices described in Example 1, infra;
  • FIG. 3 is a graphical representation of the release rates of the devices dese'fibed in Example 2, infra;
  • FIG. 4 is a graphical Representation of the release rates of tl ie devices descflled in Example 3, infra;
  • FIG. 5 l an elevational perspective view of another drug dlfir of this invlition.
  • FIG. 1 illustrates a drug dispenser, generally designated 10, of this invention.
  • Dispenser is a three layer sandwich-type laminate in the shape of a thin, circular disc comprising a core lamina 11 sandwiched between two outer laminas 12,13.
  • Core lamina 11 consists of solid particles of drug 14 dispersed within a matrix material 15.
  • Material 15 has a permeability, P, and core lamina 11 has a thickness, 21.
  • the edge 16 of core lamina 11 defines the surface area, A, thereof which is exposed to the environment.
  • Outer laminas 12,13 each have a thickness, t, and a permeability, P, to the drug.
  • Surfaces 17,18 of laminas 12,13 define a combined surface area, A, thereof which is exposed to the environment. (The area defined by the axial edges of laminas 12,13 is also exposed but is negligible relative to area A'.)
  • Dispenser 10 releases drug 14 at surfaces 16,17 and 18 by a diffusion mechanism.
  • Drug molecules initially dissolve in matrix material 15 and permeate therethrough either to exposed surface 16 or to outer laminas 12,13 and therethrough to exposed surfaces 17,18.
  • the molecules which reach exposed surfaces 16,17,18 are removed or cleared therefrom through contact with body fluids and/or body tissue.
  • the respective permeabilities and thicknesses of core lamina 11 and outer laminas 12,13 are correlated as set forth above, that is is greater than about 2, drug will be released from surfaces 17,18 at a substantially constant rate as long as matrix material 15 is saturated with the drug.
  • drug is released from edge 16 at a constantly declining rate proportional to time"?
  • the amount of drug released from edge 16 is substantially less than the amount of drug released from surfaces 17,18.
  • the overall release rate from dispenser 10 is dominated by the release rate of drug from surfaces 17,18 and thus the overall release rate approximates the substantially constant release rate from those surfaces.
  • FIG. 5 illustrates another drug dispenser, generally designated 19, of the invention.
  • Dispenser 19 is a concentric-type laminate in the shape of a cylinder comprising a cylindrical core lamina 20 and an outer concentric lamina 21 which covers the axial surface of core lamina 20.
  • Core lamina 20, like core lamina 11, comprises particles of drug 14 dispensed within a matrix material 15. It is functionally equivalent to core lamina 1 1.
  • the ends 22,23 of core lamina 20 define the surface area, A, thereof which is exposed to the environment.
  • Core lamina 20 has a diameter, 2!.
  • Outer concentric lamina 21 has a permeability, P, to the drug and has a thickness, t.
  • Lamina 21 is functionally identical to laminas 12,13 and may be made from the same materials as the latter.
  • the axial surface 24 of lamina 21 defines the surface area, A, thereof which is exposed to the environment. (The area defined by the radial edges of lamina 21 is also exposed but is negligible relative to area A'.)
  • Dispenser 19 releases drug 14 at surfaces 22,23,24 by a diffusion mechanism identical to that described above with respect to dispenser 10.
  • the correlations between the thicknesses, permeabilities and exposed surface areas of laminas 20,21 of dispenser 19 required to permit dispenser 19 to release drug at a substantially constant rate are the same as those described above. with respect to dispenser 10.
  • Drug 14 is solid (crystalline) and should have a low water solubility.
  • Low water solubility is a requirement so that the drug does not function to any significant extent as an osmotic attractant to imbibe water from the use environment into core lamina 11. If substantial water is imbibed, the drug 14 may be released by an osmotic bursting mechanism rather than a diffusion mechanism. This would affect the release rate of drug in an undesirable manner.
  • the degree of water solubility will in many-instances depend on the permeability of matrix material 15 to water. If material 15 has a high permeability tovwater, the water solubility of the drug should be correspondingly low and vice versa. Drugs which are less than about 4% by weight soluble in water are preferred.
  • the particle size of drug- 14 is notcritical. Particle sizes in the-range of l to 20p. will normally be used since they are easy to handle and may be readily dispersed homogeneously in matrix material by conventional techniques.
  • the loading of drug 14 in core lamina 11 is important because it may affect the permeability of core lamina 11 to the drug.
  • lamina 11 has a tendency to become microporous over the. devices lifetime. This occurs because as drug particles 14 dissolve in matrix 15 and diffuse therefrom, voids are left in the matrix. At such high drug loadings, the void volume is sufficient to make the portion of lamina 11 which has been v depleted of drug microporous. Such microporosity will cause the permeability of core lamina 11 to increase.
  • high drug loadings provide a means for making the permeability of the core lamina 11 substantially greater than the permeability of the outer laminas even though the same polymer is used in both.
  • the drug loading of lamina 11 will'depend upon the drug dosage regimen desired, with higher loadings providing greater dosages and/or more sustained release. Usually the loading will be in the range of 30 to 75% by weight of the core lamina.
  • Drugs which produce a localized effect at the administration site or a systemic effect at a site remote from the administration site may be used.
  • drugs include inorganic and organic compounds, for example, drugs which act on the central nervous system such as hypnotics and sedatives, psychic energizers, tranquilizers, anticonvulsants, muscle relaxants and anti-parkinson agents, antipyretics and anti-inflammatory agents, local. anesthetics,
  • anti-microbials hormonal agents, estrogenic steroids, progestational steroids, such as for contraceptive purposes, sympathomimetic drugs, cardiovascular drugs, diuretics, anti-parasitic agents, hypoglycemic drugs and ophthalmic drugs.
  • Matrix material 15 may be made from a polymeric material which'is homogeneous and substantially imperforate (i.e., it has no man-made perforations) or it may be made from a polymer which has been made microporous by conventional techniques. In either instance its permeability to the drug should be known. (Known techniques are available to determine the permeabilitiesof such materials. See for instance US. Pat. No.
  • substantially imperforate polymers which may be used are poly(butylmethacrylate), plasticized poly(vinylchloride), plasticized soft nylon, natural rubber, poly(isoprene), poly(isobutylene), poly(butadiene), poly(ethylene), poly(vinylidene chloride), cross-linked poly(vinylpyrrolidone), chlorinated poly(ethylene), poly(4,4-isopropylidene diphenylene carbonate), ethylene-vinylacetate copolymer, plasticized ethylene-vinylacetate copolymer, vinlyidene chloride-acrylonitrile copolymer, vinyl chloride-diethyl fumerate copolymer, silicone rubbers, especially the medical grade poly(dimethylsiloxanes), ethylene-propylene rubber, silicone-carbonate copolymers and vinylidene chloridevinyl chloride copolymer.
  • Microporous materials have pores which range in size from at least about 10 A to several hundred microns, but usually not more than about 100 microns.
  • materials from which microporous structures may be made are regenerated, insoluble, nonerodible cellulose, acylated cellulose, esterified cellulose, cellulose acetate propionate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose acetate diethylaminoacetate, poly(urethanes), poly(carbonates), modified insoluble collagen, cross-linked poly(- vinyl alcohol), epoxy resins and poly(olefins) or poly(- vinylchlorides).
  • These materials may be made microporous by well known procedures such as coprecipitation or leaching out incorporated salts, soap micelles, starch or like materials. See, for example, J. D. Ferry, Chemical Reviews, 18, 373 (1935), and In: Synthetic Polymer Membranes, by R. E. Kesting, McGraw-Hill, 1971.
  • Outer laminas 12,13 may be made from the same polymers as matrix material 15, provided, of course, that the permeability of the material 15 to the drug is greater than the permeability of the material forming laminas, 12,13. It will be appreciated that either of outer laminas 12,13 may be made from a drugimpermeable material. In such an instance, the effective thickness (the maximum thickness through which the drug must permeate to reach a permeable outer lamina) of core lamina 11 will be twice that of an embodiment in which both laminas 12,13 are drug permeable and the exposed outer lamina surface area from which drug is released will be half that of an embodiment in which both laminas 12,13 are drug permeable. It is also within the scope of this invention to make laminas 12,13 from different polymeric materials of different drug permeability and to make them of different thicknesses.
  • the shape and size of the dispenser of this invention will depend upon the environment in which it is intended to be used. If the dispenser is intended to be implanted or inserted, its size and shape will be compatible with the size and shape of the implantation or insertion site. For instance, if it is intended to be used as an ocular insert, it will be sized and shaped for insertion and retention in the eye. Likewise, if intended for insertion in other body cavities, such as the vagina, uterus, mouth and gastrointestinal tract, it will be sized and shaped accordingly. In most instances it will be acceptable to employ regular shapes. As indicated above, the value of k in the expression will depend on the geometrical shape of the dispenser.
  • k has a value of 4. Its value for other sandwich-type dispensers of regular geometrical shape may be calculated, (e.g., for a circle it is 8). For cylindrical concentric laminate dispensers such as are listed above as useful for dispenser 19, k has a value of /s. The value of k for other concentric laminates of other cross-sectional shapes (e.g., hexagonal, square, elliptical) may be calculated.
  • the sandwich-type laminates of this invention may be manufactured according to well-known techniques. Depending upon the particular polymers comprising the core lamina and outer laminas, the laminate may be bonded together with or without binders. Various binders are well known in the art. See for instance the Encyclopedz'a of Polymer Science and Technology, John Wiley & Sons, Vol. 8, 1968. If a binder is used, it, of course, should be compatible with the polymers constituting the laminas and should not affect or interfere with the drug permeation through the laminas or alter the drug deleteriously in any manner. Conventional laminating machines and techniques may be used, with the particular temperatures and pressures employed varying with the polymers involved.
  • the laminates may be formed as continuous sheets and the dispensers of this invention cut or punched therefrom by known techniques.
  • the concentric-type laminates of the invention may also be formed by well-known techniques such as coextrusion.
  • dispensers for releasing drugs for human or animal therapy, it will also be appreciated that they may be used to release other active agents in other environments, provided such agents are solid and have low water solubility as described above.
  • active agents include, for example, pesticides, herbicides, germicides, biocides, algicides, rodenticides, fungicides, insecticides, anti-oxidants, plant growth promoters and inhibitors, preservatives, surfactants, disinfectants, catalysts, fermentation agents, nutrients, plant minerals, sex sterilants, plant hormones, air purifiers, microorganism attenuators and the like.
  • Example 1 A A physostigmine (Eserine) dispenser, such as might be inserted in the eye to dispense Eserine thereto, was made as follows. Fifty parts Eserine (particle size approximately 5 microns), and 50 parts of ethylene/vinyl acetate copolymer (brand name, Elvax 40) were mixed homogeneously on a rubber mill. The resulting mixture was melt pressed into a 200 micron thick film. This film was then placed in a vacuum/heat laminator and a 150 micron thick sheet of ethylene/vinyl acetate copolymer (brand name, Elvax 40) was laminated to each side of it.
  • Eserine particle size approximately 5 microns
  • ethylene/vinyl acetate copolymer brand name, Elvax 40
  • the release rates of the dispensers of A, B and C were determined by placing individual devices in polymer mesh bags and suspending the bags from a vertically reciprocating bar into vessels containing 50 ml water stirred at 37C.
  • the Eserine concentration in the water was measured at regular intervals by UV analysis, the water being changed after each measurement. Eserine release rates were calculated from the measurements.
  • FIG. 2 is a plot of these release rates versus time. As indicated by the plots of FIG. 2, the release rate of the dispensers of B is substantially more constant than that of the dispensers of C and that of A is even more constant than B. This is a reflection of the increasing value of the expression P r P as reported in Table 1.
  • Example 2 Two sets of chloramphenicol dispensers were made by the general procedure of Example 1A.
  • the core lamina was made from 66 parts chloramphenicol (particle size approximately 5 microns) and 34 parts copolymer and was 125 microns thick.
  • the outer laminas were 50 microns thick and 17.5 microns thick, respectively.
  • the data for these two sets, designated 2A and 2B, are reported in Table 2 below.
  • Example 3 Table 3 P P A A P I k A 2 (cm) (cm I P A The release rates of dispensers 3A and 3B were determined by the procedure described in Example 1.
  • FIG. 4 is a plot of these release rates versus time.
  • An active agent dispenser comprising a laminate of:
  • At least one outer lamina made of an active agent release rate controlling polymer having a permeability, P, to the agent, a thickness, 1, and an exposed surface area, A', from which agent is released wherein is greater than about 2 and is at least three times .L'... r P
  • the drug dispenser of claim 2 wherein the drug is chloramphenicol, physostigmine or hydrocortisone, and the dispenser is sized and shaped for insertion in the cul-de-sac of a human eye.
  • dispenser of claim 1 wherein the dispenser is a three layer sandwich-type laminate, said core lamina being sandwiched between a pair of said outer lamina.
  • dispenser of claim 1 wherein the dispenser is a concentric-type laminate, said outer lamina being outerly concentric to said core lamina and covering the axial surface of said core lamina.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Nanotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US523720A 1974-11-14 1974-11-14 Laminated drug dispenser Expired - Lifetime US3926188A (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
US523720A US3926188A (en) 1974-11-14 1974-11-14 Laminated drug dispenser
GB4228975A GB1477813A (en) 1974-11-14 1975-10-15 Sustained release dispensers
DE2549856A DE2549856C2 (de) 1974-11-14 1975-11-06 Wirkstoffspender und Verfahren zu seiner Herstellung
IT69740/75A IT1050619B (it) 1974-11-14 1975-11-06 Erogatore a cessione prolungata particolarmente per medicamenti.. e procedimento per la sua fabbricazione
CA239,459A CA1056685A (en) 1974-11-14 1975-11-12 Active agent dispenser and process for making same
JP50136148A JPS6059203B2 (ja) 1974-11-14 1975-11-12 積層型ディスペンサ−の製造法
CH1472575A CH634226A5 (de) 1974-11-14 1975-11-13 Wirkstoffspender und verfahren zu seiner herstellung.
SE7512744A SE439432B (sv) 1974-11-14 1975-11-13 Forfarande for framstellning av en anordning for avgivande av ett aktivt medel med lag vattenloslighet genom diffusion ur ett polymerskelett
MX161923A MX158868A (es) 1974-11-14 1975-11-14 Dispensador de agente activo
MX6132A MX158867A (es) 1974-11-14 1975-11-14 Procedimiento para hacer un dispensador de agente activo
FR7534821A FR2290891A1 (fr) 1974-11-14 1975-11-14 Support destine a liberer lentement un corps actif, en particulier un medicament, et sa fabrication

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US523720A US3926188A (en) 1974-11-14 1974-11-14 Laminated drug dispenser

Publications (1)

Publication Number Publication Date
US3926188A true US3926188A (en) 1975-12-16

Family

ID=24086191

Family Applications (1)

Application Number Title Priority Date Filing Date
US523720A Expired - Lifetime US3926188A (en) 1974-11-14 1974-11-14 Laminated drug dispenser

Country Status (10)

Country Link
US (1) US3926188A (es)
JP (1) JPS6059203B2 (es)
CA (1) CA1056685A (es)
CH (1) CH634226A5 (es)
DE (1) DE2549856C2 (es)
FR (1) FR2290891A1 (es)
GB (1) GB1477813A (es)
IT (1) IT1050619B (es)
MX (2) MX158867A (es)
SE (1) SE439432B (es)

Cited By (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4182330A (en) * 1977-07-25 1980-01-08 Alza Corporation Means for administering amphipathic medicament
EP0025699A1 (en) * 1979-09-12 1981-03-25 Eli Lilly And Company Device for drug delivery to ruminants
US4304232A (en) * 1979-03-14 1981-12-08 Alza Corporation Unit system having multiplicity of means for dispensing useful agent
US4314557A (en) * 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
DE3115763A1 (de) * 1981-04-18 1982-11-04 Edgar Dr.med. 6238 Hofheim Lenhard Medizinische depotsonde zur lokalen protrahierten wirkstoffreisetzung
US4370313A (en) * 1981-10-26 1983-01-25 Eaton Laboratories, Inc. Nitrofurantoin dosage form
US4483846A (en) * 1982-02-05 1984-11-20 Ono Pharmaceutical Co., Ltd. Long-lasting three-layered pharmaceutical film preparations
US4552751A (en) * 1980-10-17 1985-11-12 Ono Pharmaceutical Co., Ltd. Long-lasting multi-layered film preparation
US4564364A (en) * 1983-05-26 1986-01-14 Alza Corporation Active agent dispenser
US4571039A (en) * 1983-04-15 1986-02-18 Stanley Poler Eye-medicating contact-lens construction
DE3538038A1 (de) * 1984-10-26 1986-04-30 Alza Corp., Palo Alto, Calif. Vorrichtung zur verabreichung eines wirkstoffs an das kolon
US4601893A (en) * 1984-02-08 1986-07-22 Pfizer Inc. Laminate device for controlled and prolonged release of substances to an ambient environment and method of use
US4639244A (en) * 1983-05-03 1987-01-27 Nabil I. Rizk Implantable electrophoretic pump for ionic drugs and associated methods
US4693895A (en) * 1984-10-26 1987-09-15 Alza Corporation Colon delivery system
WO1989003232A1 (en) * 1987-10-09 1989-04-20 Bukh Meditec A/S A medical device for introduction into a body cavity
US4830860A (en) * 1986-10-30 1989-05-16 Pfizer Inc. Stressed polymeric device for controlled release of a substance to an ambient environment
US4841968A (en) * 1986-09-26 1989-06-27 Southern Research Institute Antithrombotic/thrombolytic suture and methods of making and using the same
US4863445A (en) * 1984-07-30 1989-09-05 Baxter Travenol Laboratories, Inc. Assembly for inhibiting microbial growth in collected fluid
EP0293066A3 (en) * 1987-05-27 1989-10-11 Alza Corporation Dispenser comprising displaceable matrix with solid state properties
US4880633A (en) * 1986-03-12 1989-11-14 Merck & Co., Inc. Transdermal drug delivery system
US4906475A (en) * 1988-02-16 1990-03-06 Paco Pharmaceutical Services Estradiol transdermal delivery system
US4908027A (en) * 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4938759A (en) * 1986-09-02 1990-07-03 Alza Corporation Transdermal delivery device having a rate controlling adhesive
US4959208A (en) * 1987-10-19 1990-09-25 Ppg Industries, Inc. Active agent delivery device
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
US4994275A (en) * 1988-07-05 1991-02-19 Pfizer Inc. Veterinary devices
US5004610A (en) * 1988-06-14 1991-04-02 Alza Corporation Subsaturated nicotine transdermal therapeutic system
US5035886A (en) * 1987-10-19 1991-07-30 Ppg Industries, Inc. Active agent delivery device
US5053227A (en) * 1989-03-22 1991-10-01 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5059426A (en) * 1989-03-22 1991-10-22 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5071645A (en) * 1987-10-19 1991-12-10 Ppg Industries, Inc. Process of producing an active agent delivery device
US5088505A (en) * 1987-08-08 1992-02-18 Akzo N.V. Contraceptive implant
WO1992002211A1 (en) * 1990-08-09 1992-02-20 Endocon, Inc. Multiple drug delivery system
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5217718A (en) * 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5342623A (en) * 1986-09-12 1994-08-30 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US5466233A (en) * 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
US5508038A (en) * 1990-04-16 1996-04-16 Alza Corporation Polyisobutylene adhesives for transdermal devices
EP0710491A1 (en) * 1994-11-02 1996-05-08 The Population Council, Center For Biomedical Research Subdermally implantable device
EP0684815A4 (en) * 1993-02-19 1997-04-23 Sam S Ahn HOLLOW FIBER DRUG ADMINISTRATION SYSTEM.
US20020148138A1 (en) * 2001-04-06 2002-10-17 Egan Brian A. Smart tread boot covers
US20030157140A1 (en) * 2000-05-26 2003-08-21 Kanji Takada Nonoral preparation having three-layer structure
US20040210208A1 (en) * 2003-04-16 2004-10-21 Cook Incorporated Medical device with therapeutic agents
WO2005110364A3 (en) * 2004-04-30 2006-07-13 Allergan Inc Drug delivery systems and methods for treatment of an eye
WO2006040141A3 (de) * 2004-10-12 2006-10-05 Capsulution Nanoscience Ag Segmentierte vorrichtung für die verzögerte freisetzung von molekülen in tangentialer richtung durch dünne filme und anwendungen derselben
US20070043332A1 (en) * 2003-07-10 2007-02-22 Galen (Chemiclas) Liimited Intravaginal drug delivery devices
USRE39588E1 (en) 1987-11-09 2007-04-24 Alza Corporation Transdermal drug delivery device
US7585517B2 (en) * 2003-09-18 2009-09-08 Macusight, Inc. Transscleral delivery
US20110066141A1 (en) * 2009-09-11 2011-03-17 Cook Incorporated Implantable medical device having an anti-gastric distress agent
US20110098797A1 (en) * 2009-10-23 2011-04-28 Cleek Robert L Drug eluting composite
US20110112618A1 (en) * 2009-11-09 2011-05-12 Cleek Robert L Drug eluting composite
WO2011116132A1 (en) 2010-03-16 2011-09-22 Titan Pharmaceuticals, Inc. Heterogeneous implantable devices for drug delivery
US8222271B2 (en) 2006-03-23 2012-07-17 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
US8277830B2 (en) 2009-01-29 2012-10-02 Forsight Vision4, Inc. Posterior segment drug delivery
US8367097B2 (en) 2005-02-09 2013-02-05 Santen Pharmaceutical Co., Ltd. Liquid formulations for treatment of diseases or conditions
US8486052B2 (en) 2001-06-12 2013-07-16 The Johns Hopkins University School Of Medicine Reservoir device for intraocular drug delivery
US8492400B2 (en) 2006-02-09 2013-07-23 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US8715712B2 (en) 2011-09-14 2014-05-06 Forsight Vision5, Inc. Ocular insert apparatus and methods
US20140271783A1 (en) * 2011-10-14 2014-09-18 Purdue Research Foundation Prefabricated pharmaceutical dosage forms from functional polymer films
US8905963B2 (en) 2010-08-05 2014-12-09 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US20160067178A1 (en) * 2014-09-08 2016-03-10 ProMed Pharma, LLC Methods for manufacturing implants
US9421126B2 (en) 2009-06-03 2016-08-23 Forsight Vision5, Inc. Anterior segment drug delivery
US9474756B2 (en) 2014-08-08 2016-10-25 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US9492315B2 (en) 2010-08-05 2016-11-15 Forsight Vision4, Inc. Implantable therapeutic device
US9504771B2 (en) 2009-11-09 2016-11-29 W. L. Gore & Associates, Inc. Drug eluting composite
US9526654B2 (en) 2013-03-28 2016-12-27 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US9750636B2 (en) 2012-10-26 2017-09-05 Forsight Vision5, Inc. Ophthalmic system for sustained release of drug to eye
US9883968B2 (en) 2011-09-16 2018-02-06 Forsight Vision4, Inc. Fluid exchange apparatus and methods
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
US10398592B2 (en) 2011-06-28 2019-09-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
US10500091B2 (en) 2014-11-10 2019-12-10 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
US10617557B2 (en) 2010-08-05 2020-04-14 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
US10874548B2 (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US11224602B2 (en) 2015-04-13 2022-01-18 Forsight Vision5, Inc. Ocular insert composition of a semi-crystalline or crystalline pharmaceutically active agent
US11419759B2 (en) 2017-11-21 2022-08-23 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use
US11432959B2 (en) 2015-11-20 2022-09-06 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
US11617680B2 (en) 2016-04-05 2023-04-04 Forsight Vision4, Inc. Implantable ocular drug delivery devices
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH667001A5 (de) * 1985-09-03 1988-09-15 Hugo Degen Untermatratze.
JPS63143581A (ja) * 1986-12-05 1988-06-15 Nissha Printing Co Ltd ホログラム成型品
JPH0444666U (es) * 1990-08-22 1992-04-15
JPH0444601U (es) * 1990-08-22 1992-04-15
JP3720386B2 (ja) * 1993-12-27 2005-11-24 住友製薬株式会社 薬物放出制御製剤

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2928770A (en) * 1958-11-28 1960-03-15 Frank M Bardani Sustained action pill
US3184386A (en) * 1958-05-02 1965-05-18 Burroughs Wellcome Co Prolonged action medicinal tablets
US3416530A (en) * 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US3618604A (en) * 1969-06-09 1971-11-09 Alza Corp Ocular insert
US3625214A (en) * 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US3797485A (en) * 1971-03-26 1974-03-19 Alza Corp Novel drug delivery device for administering drug into blood circulation in blood vessel
US3851648A (en) * 1973-10-11 1974-12-03 Mead Johnson & Co Zero-order release device

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) * 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3630200A (en) * 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3832252A (en) * 1970-09-29 1974-08-27 T Higuchi Method of making a drug-delivery device

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3184386A (en) * 1958-05-02 1965-05-18 Burroughs Wellcome Co Prolonged action medicinal tablets
US2928770A (en) * 1958-11-28 1960-03-15 Frank M Bardani Sustained action pill
US3416530A (en) * 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US3618604A (en) * 1969-06-09 1971-11-09 Alza Corp Ocular insert
US3625214A (en) * 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US3797485A (en) * 1971-03-26 1974-03-19 Alza Corp Novel drug delivery device for administering drug into blood circulation in blood vessel
US3851648A (en) * 1973-10-11 1974-12-03 Mead Johnson & Co Zero-order release device

Cited By (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4182330A (en) * 1977-07-25 1980-01-08 Alza Corporation Means for administering amphipathic medicament
US4304232A (en) * 1979-03-14 1981-12-08 Alza Corporation Unit system having multiplicity of means for dispensing useful agent
EP0025699A1 (en) * 1979-09-12 1981-03-25 Eli Lilly And Company Device for drug delivery to ruminants
US4314557A (en) * 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
US4552751A (en) * 1980-10-17 1985-11-12 Ono Pharmaceutical Co., Ltd. Long-lasting multi-layered film preparation
DE3115763A1 (de) * 1981-04-18 1982-11-04 Edgar Dr.med. 6238 Hofheim Lenhard Medizinische depotsonde zur lokalen protrahierten wirkstoffreisetzung
US4370313A (en) * 1981-10-26 1983-01-25 Eaton Laboratories, Inc. Nitrofurantoin dosage form
US4483846A (en) * 1982-02-05 1984-11-20 Ono Pharmaceutical Co., Ltd. Long-lasting three-layered pharmaceutical film preparations
US4571039A (en) * 1983-04-15 1986-02-18 Stanley Poler Eye-medicating contact-lens construction
US4639244A (en) * 1983-05-03 1987-01-27 Nabil I. Rizk Implantable electrophoretic pump for ionic drugs and associated methods
US4564364A (en) * 1983-05-26 1986-01-14 Alza Corporation Active agent dispenser
US4601893A (en) * 1984-02-08 1986-07-22 Pfizer Inc. Laminate device for controlled and prolonged release of substances to an ambient environment and method of use
US4863445A (en) * 1984-07-30 1989-09-05 Baxter Travenol Laboratories, Inc. Assembly for inhibiting microbial growth in collected fluid
DE3538038A1 (de) * 1984-10-26 1986-04-30 Alza Corp., Palo Alto, Calif. Vorrichtung zur verabreichung eines wirkstoffs an das kolon
US4693895A (en) * 1984-10-26 1987-09-15 Alza Corporation Colon delivery system
US4880633A (en) * 1986-03-12 1989-11-14 Merck & Co., Inc. Transdermal drug delivery system
US4938759A (en) * 1986-09-02 1990-07-03 Alza Corporation Transdermal delivery device having a rate controlling adhesive
US5342623A (en) * 1986-09-12 1994-08-30 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4908027A (en) * 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4841968A (en) * 1986-09-26 1989-06-27 Southern Research Institute Antithrombotic/thrombolytic suture and methods of making and using the same
US4830860A (en) * 1986-10-30 1989-05-16 Pfizer Inc. Stressed polymeric device for controlled release of a substance to an ambient environment
EP0293066A3 (en) * 1987-05-27 1989-10-11 Alza Corporation Dispenser comprising displaceable matrix with solid state properties
US5088505A (en) * 1987-08-08 1992-02-18 Akzo N.V. Contraceptive implant
WO1989003232A1 (en) * 1987-10-09 1989-04-20 Bukh Meditec A/S A medical device for introduction into a body cavity
US4959208A (en) * 1987-10-19 1990-09-25 Ppg Industries, Inc. Active agent delivery device
US5035886A (en) * 1987-10-19 1991-07-30 Ppg Industries, Inc. Active agent delivery device
US5071645A (en) * 1987-10-19 1991-12-10 Ppg Industries, Inc. Process of producing an active agent delivery device
USRE39588E1 (en) 1987-11-09 2007-04-24 Alza Corporation Transdermal drug delivery device
US4906475A (en) * 1988-02-16 1990-03-06 Paco Pharmaceutical Services Estradiol transdermal delivery system
US5633008A (en) * 1988-06-14 1997-05-27 Osborne; James L. Method of administering nicotine transdermally
US5004610A (en) * 1988-06-14 1991-04-02 Alza Corporation Subsaturated nicotine transdermal therapeutic system
US6165497A (en) * 1988-06-14 2000-12-26 Alza Corporation Subsaturated nicotine transdermal therapeutic system
US4994275A (en) * 1988-07-05 1991-02-19 Pfizer Inc. Veterinary devices
US5059426A (en) * 1989-03-22 1991-10-22 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5053227A (en) * 1989-03-22 1991-10-01 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5217718A (en) * 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
LT3753B (en) 1989-08-18 1996-03-25 Cygnus Therapeutic System Device for administering dexmedetomidine transdermally
US5508038A (en) * 1990-04-16 1996-04-16 Alza Corporation Polyisobutylene adhesives for transdermal devices
WO1992002211A1 (en) * 1990-08-09 1992-02-20 Endocon, Inc. Multiple drug delivery system
EP0684815A4 (en) * 1993-02-19 1997-04-23 Sam S Ahn HOLLOW FIBER DRUG ADMINISTRATION SYSTEM.
US5466233A (en) * 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
EP0710491A1 (en) * 1994-11-02 1996-05-08 The Population Council, Center For Biomedical Research Subdermally implantable device
US5660848A (en) * 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device
US5756115A (en) * 1994-11-02 1998-05-26 The Population Coucil, Center For Biomedical Research Contraceptive method using a subdermally implantable device
US7695729B2 (en) * 2000-05-26 2010-04-13 Kanji Takada Nonoral preparation having three-layer structure
US20030157140A1 (en) * 2000-05-26 2003-08-21 Kanji Takada Nonoral preparation having three-layer structure
US20020148138A1 (en) * 2001-04-06 2002-10-17 Egan Brian A. Smart tread boot covers
US9522082B2 (en) 2001-06-12 2016-12-20 The Johns Hopkins University Reservoir device for intraocular drug delivery
US10470924B2 (en) 2001-06-12 2019-11-12 The Johns Hopkins University Reservoir device for intraocular drug delivery
US9180046B2 (en) 2001-06-12 2015-11-10 The Johns Hopkins University School Of Medicine Reservoir device for intraocular drug delivery
US8486052B2 (en) 2001-06-12 2013-07-16 The Johns Hopkins University School Of Medicine Reservoir device for intraocular drug delivery
US7306580B2 (en) 2003-04-16 2007-12-11 Cook Incorporated Medical device with therapeutic agents
US7780647B2 (en) 2003-04-16 2010-08-24 Cook Incorporated Medical device with therapeutic agents
US20040210208A1 (en) * 2003-04-16 2004-10-21 Cook Incorporated Medical device with therapeutic agents
WO2004093962A1 (en) * 2003-04-16 2004-11-04 Cook Incorporated Medical device with therapeutic agents.
US20080051737A1 (en) * 2003-04-16 2008-02-28 Cook Incorporated Medical device with therapeutic agents
US20070043332A1 (en) * 2003-07-10 2007-02-22 Galen (Chemiclas) Liimited Intravaginal drug delivery devices
US7585517B2 (en) * 2003-09-18 2009-09-08 Macusight, Inc. Transscleral delivery
WO2005110364A3 (en) * 2004-04-30 2006-07-13 Allergan Inc Drug delivery systems and methods for treatment of an eye
WO2006040141A3 (de) * 2004-10-12 2006-10-05 Capsulution Nanoscience Ag Segmentierte vorrichtung für die verzögerte freisetzung von molekülen in tangentialer richtung durch dünne filme und anwendungen derselben
US20090117170A1 (en) * 2004-10-12 2009-05-07 Capsulution Nanoscience Ag Segmented device for the delayed release of molecules in a tangential direction through thin films and uses thereof
US9387165B2 (en) 2005-02-09 2016-07-12 Santen Pharmaceutical Co., Ltd. Rapamycin formulations and methods of their use
US9381153B2 (en) 2005-02-09 2016-07-05 Santen Pharmaceutical Co., Ltd. Liquid formulations for treatment of diseases or conditions
US8927005B2 (en) 2005-02-09 2015-01-06 Santen Pharmaceutical Co., Ltd. Liquid formulations for treatment of diseases or conditions
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US8367097B2 (en) 2005-02-09 2013-02-05 Santen Pharmaceutical Co., Ltd. Liquid formulations for treatment of diseases or conditions
US8637070B2 (en) 2005-02-09 2014-01-28 Santen Pharmaceutical Co., Ltd. Rapamycin formulations and methods of their use
US8492400B2 (en) 2006-02-09 2013-07-23 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
US8658667B2 (en) 2006-02-09 2014-02-25 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
US8222271B2 (en) 2006-03-23 2012-07-17 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
US8486960B2 (en) 2006-03-23 2013-07-16 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
US9452156B2 (en) 2006-03-23 2016-09-27 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
US8277830B2 (en) 2009-01-29 2012-10-02 Forsight Vision4, Inc. Posterior segment drug delivery
US9851351B2 (en) 2009-01-29 2017-12-26 Forsight Vision4, Inc. Posterior segment drug delivery
US8795712B2 (en) 2009-01-29 2014-08-05 Forsight Vision4, Inc. Posterior segment drug delivery
US8808727B2 (en) 2009-01-29 2014-08-19 Forsight Vision4, Inc. Posterior segment drug delivery
US10813788B2 (en) 2009-01-29 2020-10-27 Forsight Vision4, Inc. Implantable therapeutic device
US10656152B2 (en) 2009-01-29 2020-05-19 Forsight Vision4, Inc. Posterior segment drug delivery
US9417238B2 (en) 2009-01-29 2016-08-16 Forsight Vision4, Inc. Posterior segment drug delivery
US11642310B2 (en) 2009-01-29 2023-05-09 Forsight Vision4, Inc. Posterior segment drug delivery
US8399006B2 (en) 2009-01-29 2013-03-19 Forsight Vision4, Inc. Posterior segment drug delivery
US9066779B2 (en) 2009-01-29 2015-06-30 Forsight Vision4, Inc. Implantable therapeutic device
US8298578B2 (en) 2009-01-29 2012-10-30 Forsight Vision4, Inc. Posterior segment drug delivery
US10736774B2 (en) 2009-06-03 2020-08-11 Forsight Vision5, Inc. Anterior segment drug delivery
US10004636B2 (en) 2009-06-03 2018-06-26 Forsight Vision5, Inc. Anterior segment drug delivery
US9421126B2 (en) 2009-06-03 2016-08-23 Forsight Vision5, Inc. Anterior segment drug delivery
US20110066141A1 (en) * 2009-09-11 2011-03-17 Cook Incorporated Implantable medical device having an anti-gastric distress agent
US20110098797A1 (en) * 2009-10-23 2011-04-28 Cleek Robert L Drug eluting composite
US20110112618A1 (en) * 2009-11-09 2011-05-12 Cleek Robert L Drug eluting composite
US9504771B2 (en) 2009-11-09 2016-11-29 W. L. Gore & Associates, Inc. Drug eluting composite
US9320890B2 (en) 2009-11-09 2016-04-26 W. L. Gore & Associates, Inc. Drug eluting composite
US10039863B2 (en) 2009-11-09 2018-08-07 W. L. Gore & Associates, Inc. Drug eluting composite
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
WO2011116132A1 (en) 2010-03-16 2011-09-22 Titan Pharmaceuticals, Inc. Heterogeneous implantable devices for drug delivery
US10123971B2 (en) 2010-03-16 2018-11-13 Titan Pharmaceuticals, Inc. Heterogeneous implantable devices for drug delivery
US10111830B2 (en) 2010-03-16 2018-10-30 Titan Pharmaceuticals, Inc. Heterogeneous implantable devices for drug delivery
US9937073B2 (en) 2010-06-01 2018-04-10 Forsight Vision5, Inc. Ocular insert apparatus and methods
US8939948B2 (en) 2010-06-01 2015-01-27 Forsight Vision5, Inc. Ocular insert apparatus and methods
US9861521B2 (en) 2010-08-05 2018-01-09 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US10265215B2 (en) 2010-08-05 2019-04-23 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US8905963B2 (en) 2010-08-05 2014-12-09 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US9033911B2 (en) 2010-08-05 2015-05-19 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US11679027B2 (en) 2010-08-05 2023-06-20 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
US11786396B2 (en) 2010-08-05 2023-10-17 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US9492315B2 (en) 2010-08-05 2016-11-15 Forsight Vision4, Inc. Implantable therapeutic device
US10617557B2 (en) 2010-08-05 2020-04-14 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
US10874548B2 (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US11065151B2 (en) 2010-11-19 2021-07-20 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US10398592B2 (en) 2011-06-28 2019-09-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
US11813196B2 (en) 2011-06-28 2023-11-14 Forsight Vision4, Inc. Diagnostic methods and apparatus
US10835416B2 (en) 2011-09-14 2020-11-17 Forsight Vision5, Inc. Ocular insert apparatus and methods
US8715712B2 (en) 2011-09-14 2014-05-06 Forsight Vision5, Inc. Ocular insert apparatus and methods
US9883968B2 (en) 2011-09-16 2018-02-06 Forsight Vision4, Inc. Fluid exchange apparatus and methods
US10653554B2 (en) 2011-09-16 2020-05-19 Forsight Vision4, Inc. Fluid exchange apparatus and methods
US20140271783A1 (en) * 2011-10-14 2014-09-18 Purdue Research Foundation Prefabricated pharmaceutical dosage forms from functional polymer films
US10456293B2 (en) 2012-10-26 2019-10-29 Forsight Vision5, Inc. Ophthalmic system for sustained release of drug to eye
US9750636B2 (en) 2012-10-26 2017-09-05 Forsight Vision5, Inc. Ophthalmic system for sustained release of drug to eye
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US9526654B2 (en) 2013-03-28 2016-12-27 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US12115102B2 (en) 2013-03-28 2024-10-15 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US10398593B2 (en) 2013-03-28 2019-09-03 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US11510810B2 (en) 2013-03-28 2022-11-29 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US10765677B2 (en) 2014-08-08 2020-09-08 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US9895369B2 (en) 2014-08-08 2018-02-20 Forsight Vision4, Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US10363255B2 (en) 2014-08-08 2019-07-30 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US9474756B2 (en) 2014-08-08 2016-10-25 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US20160067178A1 (en) * 2014-09-08 2016-03-10 ProMed Pharma, LLC Methods for manufacturing implants
US10226419B2 (en) * 2014-09-08 2019-03-12 ProMed Pharma, LLC Methods for manufacturing implants
US11110001B2 (en) 2014-11-10 2021-09-07 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
US10500091B2 (en) 2014-11-10 2019-12-10 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
US12251336B2 (en) 2014-11-10 2025-03-18 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
US11224602B2 (en) 2015-04-13 2022-01-18 Forsight Vision5, Inc. Ocular insert composition of a semi-crystalline or crystalline pharmaceutically active agent
US11432959B2 (en) 2015-11-20 2022-09-06 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
US12201556B2 (en) 2015-11-20 2025-01-21 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
US11617680B2 (en) 2016-04-05 2023-04-04 Forsight Vision4, Inc. Implantable ocular drug delivery devices
US12102560B2 (en) 2016-04-05 2024-10-01 Forsight Vision4, Inc. Implantable ocular drug delivery devices
US11419759B2 (en) 2017-11-21 2022-08-23 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device

Also Published As

Publication number Publication date
CH634226A5 (de) 1983-01-31
JPS5170807A (es) 1976-06-18
SE439432B (sv) 1985-06-17
MX158868A (es) 1989-03-27
GB1477813A (en) 1977-06-29
MX158867A (es) 1989-03-27
DE2549856C2 (de) 1985-01-03
FR2290891B1 (es) 1978-11-10
JPS6059203B2 (ja) 1985-12-24
FR2290891A1 (fr) 1976-06-11
DE2549856A1 (de) 1976-05-20
CA1056685A (en) 1979-06-19
IT1050619B (it) 1981-03-20
SE7512744L (sv) 1977-05-15

Similar Documents

Publication Publication Date Title
US3926188A (en) Laminated drug dispenser
US3995631A (en) Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US4278087A (en) Device with integrated operations for controlling release of agent
US3732865A (en) Osmotic dispenser
US4034756A (en) Osmotically driven fluid dispenser
US4177256A (en) Osmotic bursting drug delivery device
CA1047403A (en) Process for making a monolithic drug delivery device
US3845770A (en) Osmatic dispensing device for releasing beneficial agent
US4142526A (en) Osmotic releasing system with means for changing release therefrom
US3760805A (en) Osmotic dispenser with collapsible supply container
EP0266929B1 (en) Stressed polymeric device for controlled release of a substance to an ambient environment
US3916899A (en) Osmotic dispensing device with maximum and minimum sizes for the passageway
US3760984A (en) Osmotically powered agent dispensing device with filling means
US3760806A (en) Helical osmotic dispenser with non-planar membrane
AU670410B2 (en) Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset
US4601893A (en) Laminate device for controlled and prolonged release of substances to an ambient environment and method of use
US3760804A (en) Improved osmotic dispenser employing magnesium sulphate and magnesium chloride
US4327725A (en) Osmotic device with hydrogel driving member
US4217898A (en) System with microporous reservoir having surface for diffusional delivery of agent
US4067961A (en) Controlled release article
US4786500A (en) Programmable agent delivery system
US4127127A (en) Therapeutic systems made from certain segmented copolyesters
GB1565678A (en) Implatable vaginal medicament dispenser
GB1565677A (en) Implantable vaginal medicament dispenser
IE61788B1 (en) Transdermal therapeutic system